The insider activity is routine and small in scale, typical of planned or tax-driven transactions rather than a signal of material concern. Traders should not interpret this cluster as a negative catalyst. Monitor for any pattern of increasing sales or commentary around liquidity needs.
CGEN drugs
CGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 14 $2.88entry
- T+1 · 7mo ago +0.35%α −0.43% · $2.89
- T+5 · 7mo ago −1.39%α −2.78% · $2.84
- T+20 · 6mo ago −0.35%α −6.64% · $2.87
- T+60 · 4mo ago −14.24%α −22.76% · $2.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two corporate insiders at Compugen Ltd, CEO Ophir Eran and SVP Levine Zurit, sold shares in open-market transactions totaling $20,000 over a 7-day window. These sales were accompanied by multiple derivative exercises, some of which triggered tax-related share dispositions. The total dollar value of open-market sales is minimal relative to the company's $272M market cap.
Key Financial Metrics
Key Facts
- CEO Ophir Eran sold 5,000 shares for $14,521 and exercised 10,000 derivative shares across two transactions, one at no cost and another at $0.8292 per share.
- SVP Levine Zurit sold 8,250 shares in total for $21,625 and exercised 8,250 derivative shares across multiple transactions.
- Total open-market sales by insiders amounted to $36,146 (combined), but only $20,000 is reflected as net proceeds from selling activity after accounting for overlapping exercise-sale mechanics.
- All open-market sales occurred at prices between $2.56 and $2.90 per share.
- The total value of insider selling represents just 0.013% of the company's $272M market cap.
Financial Impact
Minimal, $20K in net open-market sales, representing 0.013% of market cap.
Risk Factors
- Misinterpreting routine, small-scale insider transactions as a bearish signal.
- Potential perception risk if future filings show escalating selling activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CGEN-1776283847848 |
Track record
9 reports on CGEN
Filters
- Nov 9, 20267d ago 6-K Neutral 4/10 Entry $2.14 Now $2.04 −4.67% settles Dec 8
- Aug 3, 202615w ago 6-K Neutral 2/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Aug 3, 202615w ago 6-K Neutral 4/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Jun 9, 202623w ago EFFECT Neutral 3/10 Entry $2.02 to $2.39 Now $2.04 +0.99% ▲ +18.32% +16.87% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $2.86 to $2.03 Now $2.04 −28.67% ▼ −29.02% −30.60% vs SPY
- Apr 24, 202629w ago Insider Cluster Neutral 2/10 Entry $3.10 to $2.61 Now $2.04 −34.19% ▼ −15.81% −19.83% vs SPY
- Apr 14, 202631w ago Insider Cluster Neutral 2/10 Viewing Entry $2.88 to $2.87 Now $2.04 −29.17% ▼ −0.35% −6.64% vs SPY
- Apr 13, 202631w ago 144 Neutral 3/10 Entry $2.76 to $2.87 Now $2.04 −26.09% ▲ +3.99% −3.74% vs SPY
- Mar 26, 202633w ago Insider Cluster Neutral 3/10 Entry $2.06 to $3.10 Now $2.04 −0.97% ▲ +50.49% +39.82% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers